Research programme: transdermal NSAIDs - SK Drug Development Center

Drug Profile

Research programme: transdermal NSAIDs - SK Drug Development Center

Alternative Names: YKPPN

Latest Information Update: 10 Jul 2009

Price : $50

At a glance

  • Originator SK Bio-Pharmaceuticals
  • Developer SK Drug Development Center
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 01 Jan 2009 Discontinued - Preclinical for Pain in South Korea (unspecified route)
  • 17 Aug 2005 Preclinical trials in Pain in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top